SCHEMBL613290

SCHEMBL613290

OC1(Cc2ccccc2)CCNCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 2/20 0.51
OPRM1 P35372 2/20 0.51
OPRD1 P41143 1/20 0.51
OPRK1 P41145 1/20 0.51
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP2C9 P11712 1/20 0.46
TSHR P16473 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
HIF1A Q16665 1/20 0.46
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
TACR1 P25103 1/20 0.44
SLC6A2 P23975 2/20 0.43
SLC6A4 P31645 2/20 0.43
SLC6A3 Q01959 2/20 0.43
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
ADRA1D P25100 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7297666 0.98 OPRL1 (0.54) OPRL1OPRM1OPRD1OPRK1MEN1
SCHEMBL5509592 0.89 SLC6A2 (0.47) OPRL1OPRM1OPRD1OPRK1MEN1
Benzoic Acid SCHEMBL20473182 0.88 SLC6A2 (0.45) OPRL1OPRM1OPRD1OPRK1TSHR
Trifluoroacetic Acid SCHEMBL3100098 0.87 OPRL1 (0.42) OPRL1OPRM1OPRD1OPRK1MEN1
Hydrochloric Acid SCHEMBL18038811 0.87 OPRL1 (0.47) OPRL1OPRM1OPRD1OPRK1MEN1
SCHEMBL23343753 0.85 OPRL1 (0.65) OPRL1OPRM1OPRD1OPRK1MAOA
Tert-Butyl Formate SCHEMBL28313659 0.82 OPRL1 (0.42) OPRL1OPRM1OPRD1OPRK1MEN1
SCHEMBL735823 0.81 OPRL1 (0.56) OPRL1OPRM1OPRD1OPRK1ALDH1A1
SCHEMBL4206116 0.81 OPRL1 (0.56) OPRL1OPRM1OPRD1OPRK1MAOA
SCHEMBL3866792 0.81 ALDH1A1 (0.37) OPRL1OPRM1OPRD1OPRK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 528 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024079351-A1 NOVEL PIPERAZINE-BASED SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS GENECODE (EE) 2024-04-18 WO claimed
CN-114349922-B Flexible dual-cured resin composition and preparation method of molded body thereof 浙江华峰新材料有限公司 2024-01-23 CN claimed
EP-3661941-B1 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-12-14 EP claimed
EP-3672952-B1 BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-12-14 EP claimed
CN-114349922-A Flexible dual-curing resin composition and preparation method of forming body thereof 浙江华峰新材料有限公司 2022-04-15 CN claimed
EP-3363796-B1 METHOD FOR PRODUCING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2021-04-07 EP claimed
EP-1831206-B1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI PHARM INC (US) 2011-08-24 EP claimed
WO-2010022055-A2 INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2010-02-25 WO claimed
JP-2008521903-A 2008-06-26 JP claimed
CN-101193867-A N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole libraries OSI PHARM INC (US) 2008-06-04 CN claimed
EP-1831206-A2 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI Pharmaceuticals, Inc. (US) 2007-09-12 EP claimed
WO-2006060381-A2 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI PHARMACEUTICALS, INC. (US) 2006-06-08 WO claimed
US-20060116402-A1 N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library OSI PHARMACEUTICALS, INC. 2006-06-01 US claimed
EP-1441735-B1 N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE ANGELETTI P IST RICHERCHE BIO (IT) 2006-02-22 EP claimed
CN-1186332-C Novel thyroid receptor ligands and method II KAROBIO AB (SE) 2005-01-26 CN claimed
CN-1337953-A Novel thyroid receptor ligands and method II KAROBIO AB (SE) 2002-02-27 CN claimed
US-4111703-A HEAT-SENSITIVE COATING COMPOSITION WITH 4-AROMATIC AND HYDROXY SUBSTITUTED PIPERIDINE DERIVATIVE AND CYCLIC POLYKETO COMPOUND GRAPHIC CONTROLS CORPORATION (US) 1978-09-05 US claimed
US-20250281477-A1 TREATMENT OF CNS CONDITIONS TAKEDA PHARMACEUTICALS CO (JP) 2025-09-11 US disclosed
US-3998827-A HYPOTENSIVE AGENTS THE UPJOHN COMPANY (US) 1976-12-21 US disclosed
US-RE28973-E PARKINSON'S DISEASE A. H. ROBINS COMPANY, INCORPORATED (US) 1976-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250281477-A1 TREATMENT OF CNS CONDITIONS NLN, PMP22, CYP11B2 OPRL1 745/4885OPRM1 1021/4885OPRD1 887/4885
US-20060116402-A1 N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library KIT, CHUK, TNNI3K OPRL1 2233/4885OPRM1 3335/4885OPRD1 2256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.